Oral Transmucosal Drugs Market Size, Share & Analysis - 2032

Oral Transmucosal Drugs Market - By Product Type (Tablet, Film, Liquid & Spray), Route of Administration, Indication (Opioid Dependence, Nausea & Vomiting, Erectile Dysfunction, Neurological Disorders), Distribution Channel & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp;Primary

1.6.2&nbsp;&nbsp;&nbsp;Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp;Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising demand for oral transmucosal drugs

3.2.1.2&nbsp;&nbsp;&nbsp;Advancements in drug delivery technologies

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing prevalence of chronic diseases

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Stringent regulatory requirements for drug approval and commercialization

3.2.2.2&nbsp;&nbsp;&nbsp;High cost associated with research and development activities

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Technological landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.6.1&nbsp;&nbsp;&nbsp;Supplier power

3.6.2&nbsp;&nbsp;&nbsp; Buyer power

3.6.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.6.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.6.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

3.8&nbsp;&nbsp;&nbsp; Technological landscape

3.9&nbsp;&nbsp;&nbsp; Future market trends

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Tablets

5.3&nbsp;&nbsp;&nbsp; Films

5.4&nbsp;&nbsp;&nbsp; Liquid &amp; spray

5.5&nbsp;&nbsp;&nbsp; Other product types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Sublingual mucosa

6.3&nbsp;&nbsp;&nbsp; Buccal mucosa

6.4&nbsp;&nbsp;&nbsp; Other routes of administration

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Opioid dependence

7.3&nbsp;&nbsp;&nbsp; Nausea and vomiting

7.4&nbsp;&nbsp;&nbsp; Erectile dysfunction

7.5&nbsp;&nbsp;&nbsp; Neurological disorders

7.6&nbsp;&nbsp;&nbsp; Other indications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

8.3&nbsp;&nbsp;&nbsp; Retail pharmacies

8.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp;U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp;Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Italy

9.3.5&nbsp;&nbsp;&nbsp; Spain

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp;China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp;Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp;South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Aquestive Therapeutics, Inc.

10.2&nbsp;&nbsp;&nbsp; C.L.Pharm Co., Ltd.

10.3&nbsp;&nbsp;&nbsp; CURE Pharmaceutical

10.4&nbsp;&nbsp;&nbsp; IntelGenx Corp

10.5&nbsp;&nbsp;&nbsp; Jazz Pharmaceuticals

10.6&nbsp;&nbsp;&nbsp; NAL Pharma

10.7&nbsp;&nbsp;&nbsp; Novartis AG

10.8&nbsp;&nbsp;&nbsp; Pfizer Inc.

10.9&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd.

10.10&nbsp;&nbsp;&nbsp; ZIM Laboratories Limited. 
&nbsp;

Oral Transmucosal Drugs Market

Get a free sample of this report